Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
1989-7-11
|
| pubmed:abstractText |
Developments in the medical management of anxiety tend, over the last two decades, to have clustered around modifications to the early benzodiazepines. These developments have given the psychiatrist a wide range of options in terms of intensity and duration of action but have carried with them the range of penalties associated with the benzodiazepines as a group. These include among others addiction potential and a sometimes inappropriate level of sedation. The need has been for a new drug, unrelated to the benzodiazepines and which is more specifically orientated towards anxiety. Buspirone, it seems, may well be such a drug. This paper discusses the anxiety disorders, the drug management of anxiety, the problems associated with traditional anxiolytics and the recent availability of a new class of drug in this indication.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0256-9574
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
17
|
| pubmed:volume |
75
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
xxxii-iii
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1989
|
| pubmed:articleTitle |
Modern treatment modalities in anxiety.
|
| pubmed:affiliation |
West-Ros-Park Mental Health Centre, Boston, Mass.
|
| pubmed:publicationType |
Journal Article
|